Evidence map›Paper›PMID 42557936›Full record

ReviewCancer science2026

Daraxonrasib and Beyond: Pan-RAS Inhibition, Resistance, and Next-Generation Strategies.

Ryo Honda

Abstract readReview
In one paragraph

Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ryo HondaUnited Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.ORCID https://orcid.org/0000-0003-3698-5975

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS proteins have long been considered difficult therapeutic targets, but allele-selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC-6236), an oral pan-RAS inhibitor, has now extended this concept by targeting multiple mutant and wild-type RAS proteins. In the randomized phase III RASolute 302 trial, daraxonrasib substantially improved survival over chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma while maintaining manageable toxicity, thereby establishing a clinically useful therapeutic window for pan-RAS inhibition. Nevertheless, epithelial toxicity and acquired resistance, including mutations affecting ternary-complex formation and mechanisms associated with increased KRAS abundance, remain important challenges. This review discusses the mechanistic and clinical development of daraxonrasib and examines emerging strategies designed to improve the depth, durability, and selectivity of RAS suppression. These include pan-KRAS inhibitors, targeted RAS degraders, RAS-cleaving protein biologics, and tumor-directed delivery systems. Together, these approaches may reshape the treatment of RAS-driven cancers across tumor types and disease stages.

Indexed as

Daraxonrasibdrug resistancemolecular targeted therapyneoplasmpan‐RAS inhibitionRAS proteins

Identifiers

PMID42557936
PMCPMC13444396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.